FDA asks judge to toss Mylan's Lipitor suit; Biogen, Elan update PML numbers on Tysabri;

@FiercePharma: Analyst: J&J may need a $10 billion-plus deal. News | Follow @FiercePharma 

> The FDA has asked a federal judge to throw out Mylan's lawsuit seeking to force the agency to clear the way for its generic version of Pfizer's cholesterol-lowering drug Lipitor as early as June. News

> Biogen Idec and Elan have changed the labeling on their multiple sclerosis drug Tysabri to update the incidence of PML, a rare brain infection, among patients using it. Story

> Swiss drugmaker Novartis has finally sealed its $50.9 billion buy of Alcon by paying the eyecare group's minority shareholders an extra $463 million in cash. Item

> The FDA said it was not recommending changes in the use of stimulants such as Adderall XR and Ritalin to treat hyperactivity after a review of a study into potential heart disease risks from the drugs. Article

> The FDA is taking steps to strengthen protection of commercially sensitive information after an agency chemist was charged with insider trading, according to a memo provided to Reuters. Report

> The European Commission has granted marketing authorization for Trobalt, the new fast-acting epilepsy drug from GlaxoSmithKline and Valeant Pharmaceuticals. Item

> A New Jersey man pleaded guilty to participating in a scheme to traffic in stolen pharmaceutical drugs worth $8.8 million, officials said. News

> Indian drugmaker Kayem Pharmaceuticals said that it will stop selling sodium thiopental, one of three drugs used in lethal injections, to U.S. jails, as it goes against the "ethos of Hinduism." Story

> Eisai said it has established a subsidiary company in Brazil, dubbed Eisai Participações (Eisai Brazil), to be based in Sao Paulo. Report

> GlaxoSmithKline is trying out wireless technology at its pharmaceutical ingredients plant in Cork, Ireland, to see if it can cut costs by providing a better understanding of water usage. Article

> A drug-resistant hospital pathogen first identified in India two years ago has now emerged in New Delhi's water supplies. Report

Biotech News

 @FierceBiotech:  AZ wins tightly-limited FDA OK for new thyroid cancer drug. Report | Follow @FierceBiotech  

 @JohnCFierce: The FDA says that it has taken steps to safeguard data after a chemist was accused of using insider information. Story | Follow @JohnCFierce

> Patient recruitment stymies StemCells rare disease program. Story

> Big Pharma has eyes on Cerenis' HDL drug. Item 

> Vertex, CF Foundation expand alliance in $75M deal. Article 

> New superbug underscores anemic antibiotic pipeline. Item 

And Finally... Scientists should more closely examine whether antidepressant drugs increase the risk of breast and ovarian cancer, according to a researcher affiliated with Harvard University whose review of 61 studies suggested a link. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.